Redefining glucose thresholds for hypoglycaemia management in children and young adults with type 1 diabetes on automated insulin therapy: A cross‐over clinical trial protocol
Year: 2026
Type: article
Study design: Study Protocol
Abstract: Background and Aim Current international guidelines for hypoglycaemia management in Type 1 diabetes recommend initiating treatment when glucose level falls below 3.9 mmol/L. However, these recommendations were developed before widespread use of diabetes technologies. This study aims to determine whether a revised hypoglycaemia treatment approach incorporating a lower treatment threshold is non‐inferior to the standard threshold (<3.9 mmol/L) in children and young adults with Type 1 diabetes using automated insulin delivery (AID) systems. We hypothesise that the revised approach will be non‐inferior to the current standard recommendations without increasing time in clinically significant hypoglycaemia. Methods This single‐centre, randomised, two‐period, crossover, non‐inferiority trial will recruit 45 participants aged 6–25 years with Type 1 diabetes, diagnosed for at least 12 months and using AID systems. Participants will complete two 4‐week treatment periods in random order: standard hypoglycaemia treatment (<3.9 mmol/L) and revised hypoglycaemia treatment (≤3.6 mmol/L with consideration of CGM trends, active insulin, exercise and symptoms). Treatment periods will be separated by a 2‐week washout period. The primary outcome is the percentage of time spent in clinically significant hypoglycaemia (<3.0 mmol/L), measured using CGM. Secondary outcomes are CGM metrics including time in range and time above range, along with participant acceptability of the revised treatment approach. Conclusion This study will provide prospective evidence on whether a revised hypoglycaemia treatment approach can safely reduce the glucose threshold for treatment in children and young adults using AID systems. Findings may inform future recommendations for hypoglycaemia management in the era of diabetes technologies.
Source: Diabetic Medicine
DOI: 10.1111/dme.70536
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,870
OpenAlex ID: W7236663041
